Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
about
YAP-Mediated Mechanotransduction in Skeletal MuscleRASSF6; the Putative Tumor Suppressor of the RASSF FamilyA Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasRhabdomyosarcoma: Advances in Molecular and Cellular BiologyRASSF tumor suppressor gene family: biological functions and regulationFOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathwaysThe cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenesA rapid one-generation genetic screen in a Drosophila model to capture rhabdomyosarcoma effectors and therapeutic targetsNetrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability.Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesisRole of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar RhabdomyosarcomaThe Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.Muscle contraction is required to maintain the pool of muscle progenitors via YAP and NOTCH during fetal myogenesis.Effects of long term low- and high-dose sodium arsenite exposure in human transitional cells.The Hippo signal transduction network in skeletal and cardiac muscle.The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD.MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game.PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.Ras signaling through RASSF proteins.Molecular diagnostics in the management of rhabdomyosarcoma.Hippo vs. Crab: tissue-specific functions of the mammalian Hippo pathway.YAP and the Hippo pathway in pediatric cancer.TAZ and YAP are frequently activated oncoproteins in sarcomas.YAPping about differentiation therapy in muscle cancer.A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.RASSF4 controls SOCE and ER-PM junctions through regulation of PI(4,5)P2.The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.Potential Value of YAP Staining in Rhabdomyosarcoma.A review of soft-tissue sarcomas: translation of biological advances into treatment measures.Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma
P2860
Q26766774-85E6A3D3-3B9F-4220-8148-1FFDEF72527AQ26774307-38389CD0-847F-4406-8299-ED88ACD3AA38Q26782842-08E59279-D56D-499F-B9FB-EBEDE9D68DEFQ26784207-1CFA9D0B-C3A1-4BFF-8280-DC00BFEEEAA8Q26866080-C6D4A246-495A-4018-9E94-FF7C5415045BQ28076296-9DD59CED-7262-4D6F-B36E-8EA42732329FQ28649653-C66D4A94-B29B-45A1-87FB-40435E06628CQ35061929-3314DCF5-2D1B-4EDC-9320-886DDC9B88E8Q35740352-96B65FEA-41A1-4686-820E-37EF0DC8DD2FQ35818801-0226396F-BA84-4858-B322-C6EE7955F840Q35819280-F9E600AA-A8BB-40F2-806C-420B41CAA146Q36142754-431CBE56-B591-402D-B0E7-641E9417200FQ36623378-11395B15-13FF-4B2B-B178-C11855B8C6EAQ37199465-B560CF90-4F6F-4446-BA3F-50C556C59865Q37270346-92075C74-AF73-4BC7-B71F-A7F9E3639652Q37685225-E10EC226-5CA9-4E30-86D5-76FF553AEE41Q38237345-B335E0AF-8171-44F6-A4C2-71F3D610B0CCQ38255378-02EA9E29-1503-4A03-B659-A6554DB730A3Q38341214-AC430707-21B9-4F51-A495-CD684929CE13Q38552358-62FC2E4E-2549-4545-B784-4635C7AE6351Q38730193-3E564EE7-8EC4-41E6-9479-8BD0EDF4F3C8Q38862017-161457D8-B698-4BDE-AEBE-5C798C032E9FQ39069676-96403454-73BB-49F7-9287-B83403141623Q39081825-C2851D3A-0E31-4F0C-AB79-4A10AC045A0DQ39374990-710E46AD-BE15-4BBA-8EF2-2C8DF4E1C417Q41416961-5B65CCA6-AFD0-46A3-B864-C06AE3FD31B7Q42062946-1AF8AD22-3CF3-4F54-B5C1-B14C12A6DFB9Q47782462-4F661E88-FC52-4AFE-A305-D91C70E60164Q48297615-E87014BB-7445-462B-B1A4-DD75D696E86DQ51213072-AAE1F92C-8801-4754-B15E-3AEEAC7D16FAQ52668719-CE3286A7-2DE5-491C-860E-B08BDCFA4CB0Q52723273-974EE769-204D-44F7-8187-0FB7FEEAA9C1Q55265062-33B27E06-59F4-4A01-B08F-CD706FCB91C4Q57646291-8FE59E24-CAA8-4D94-8B20-866868380592
P2860
Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@en
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@nl
type
label
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@en
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@nl
prefLabel
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@en
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@nl
P2093
P2860
P356
P1476
Alveolar rhabdomyosarcoma-asso ...... via Hippo pathway suppression.
@en
P2093
Candy Chen
Corinne M Linardic
Jen-Tsan Ashley Chi
Julie Grondin Kephart
Julien Fitamant
Kathleen A Galindo
Lisa E S Crose
Nabeel Bardeesy
Rene L Galindo
Rex C Bentley
P2860
P304
P356
10.1172/JCI67087
P407
P577
2013-12-16T00:00:00Z